Issue 33: Pharma Digest
The Digest is for you, the valued members of our pharma community. Receive the latest market movements, breaking pharma news, business-critical whitepapers and content, and updates on our exclusive executive summits. Don’t forget to subscribe using the button above.
Let's get started.
Understand the opportunities, disruptions, and action required to effectively harness AI’s transformative power in Medical Technology. Join our free online panel to discover the impact of generative AI in MedTech: https://bit.ly/3V20kQn
Thanks to our panelists who will be sharing their insights:
Brandon Randall, VP of Sports Medicine R&D, Smith+Nephew
Paula Antunes, Global Regulatory Lead, Digital Health, Novo Nordisk
Rohit Alimchandani, Head of Life Sciences UK&I, Cognizant·?????
Moderator: Matic Meglic, Global Executive Director - Industry Partnerships, Novartis
Unlock the full potential of your Medical Affairs team through cross-collaboration! Our whitepaper details successful strategies for integrating R&D, commercial sectors, and Medical Affairs to drive innovation and strategic growth. Discover the benefits of collaborative synergy. Download your copy today! ???? #PharmaInnovation #Teamwork
In our latest podcast, Florent Edouard, SVP & Global Head of Customer Excellence at Grünenthal Group discusses how consistency and quality are key to delivering customer excellence. Listen here: https://bit.ly/4bOOG1Z Hear how Grunenthal are differentiating themselves via customer experience including how they’ve implemented successful omnichannel marketing #pharmaCX #HCPengagement #pharmapodcast
Top 5 pharma news to watch
- Pfizer sees lung cancer drug topping $1 billion in sales following impressive 5-year data (Reuters.com, May 31)
- Bristol Myers secures another FDA go-ahead for Breyanzi, this time in mantle cell lymphoma (Fierce Pharma, May 30)
- Novartis leukemia drug more effective than older treatments in trial (Reuters.com, May 31)
- Immunovant changes up plans for closely watched autoimmune drugs (BioPharma Dive, May 30)
- Astellas refiles CLDN 18.2 cancer drug after FDA knockback (pharmaphorum, May 31)
领英推è
Upcoming 2024 Events
Pharma Japan (September 25-26, Tokyo)
Pharma & Patient USA (October 15-16, Boston)
Pharma Customer Engagement USA (October 22-23, Philadelphia)
Pharma Customer Engagement Europe (November 4-5, London)
That rounds off Issue 33 of the Pharma Digest.
We'll be back in two weeks with more important news, market updates, pharma content, and updates on our events. Don’t forget to subscribe to receive a notification for our next bi-weekly digest.
As always, the Pharma team are on hand to answer your questions. You can connect with us on LinkedIn.
EU Team
USA Team
See you next time!